Osteoarthritis Market Size, Share, and Analysis, By Type (Hip Osteoarthritis, Knee Osteoarthritis, Foot & Ankle Osteoarthritis, Shoulder Osteoarthritis, Spinal Osteoarthritis), By Drug Type (Analgesics, Corticosteroids, Viscosupplementation agents, Nonsteroidal anti-inflammatory drugs {NSAIDS}), By Diagnosis (Imagining and Joint Fluid Analysis), By Route of Administration (Parenteral Route, Oral Route, Topical Route), By Treatment (Medication, Therapy, Surgery), By Distribution Channel (Hospitals Pharmacy, E-Commerce, Retail Pharmacy, Drug Store), By Purchasing Pattern (Prescription Drugs, Over-The-Counter Drugs) and Regional Forecasts, 2022-2032
Osteoarthritis Market Size, Share, and Analysis, By Type (Hip Osteoarthritis, Knee Osteoarthritis, Foot & Ankle Osteoarthritis, Shoulder Osteoarthritis, Spinal Osteoarthritis), By Drug Type (Analgesics, Corticosteroids, Viscosupplementation agents, Nonsteroidal anti-inflammatory drugs {NSAIDS}), By Diagnosis (Imagining and Joint Fluid Analysis), By Route of Administration (Parenteral Route, Oral Route, Topical Route), By Treatment (Medication, Therapy, Surgery), By Distribution Channel (Hospitals Pharmacy, E-Commerce, Retail Pharmacy, Drug Store), By Purchasing Pattern (Prescription Drugs, Over-The-Counter Drugs) and Regional Forecasts, 2022-2032
PRODUCT OVERVIEW:
The global Osteoarthritis market size was USD 5.85 billion in 2021 and projected to grow from USD 6.9 billion in 2023 to USD 15 billion by 2032, exhibiting a CAGR of 9.0% during the forecast period
Osteoarthritis (OA) is a common condition which affects the shoulders, fingers, knees, feet, back, hips, and neck joints. The progressive deterioration of the joint cartilage is its characteristic. OA can be identified through X-ray, medical assessment, lab tests, arthroscopic, joint fluid analysis, and magnetic resonance imaging (MRI) scans. Several surgical methods & drugs are preferred to treat the indications and symptoms. Few symptoms of OA are stiffness, discomfort, oedema, lack of flexibility, chronic pain, bone spurs, and sleep disruptions. The poor dietary habits, sedentary lifestyle, increased obesity and blood sugar levels are a major reason for acquiring OA.
MARKET HIGHLIGHTS
Osteoarthritis Market is expected to project a CAGR of 9.0% during forecast period, 2022-2032
Osteoarthritis market is expected to reach USD 15 billion at a CAGR of 9.0% during forecast period owing to the increasing awareness about Osteoarthritis and the accessibility to advanced treatments are boosting the growth of osteoarthritis treatment. The increasing demand for minimal invasive non-surgical treatments assist in the growth of the osteoarthritis market.
OSTEOARTHRITIS MARKET SEGMENTATION:
Spinal Osteoarthritis segment is expected to dominate during the forecast period
Osteoarthritis Market is classified based on the Type into Hip Osteoarthritis, Knee Osteoarthritis, Foot & Ankle Osteoarthritis, Shoulder Osteoarthritis, Spinal Osteoarthritis. Spinal Osteoarthritis segment is expected to dominate market during the forecast period owing to the increasing acquirance of sedentary lifestyles, rising obesity rates which is expected to drive the spinal osteoarthritis market growth. The rising preference of minimal invasive procedures of surgery and the advancements of new treatments are aiding in the growth of the market.
Imagining segment is expected to dominate during the forecast period
MARKET DYNAMICS:
Growth Drivers
Osteoarthritis Market is segmented based on regional analysis into five major regions: North America, Latin America, Europe, Asia Pacific and the Middle East and Africa. North America region dominated the Osteoarthritis Market in 2021 and is also expected to dominate over the forecast period owing to the increasing awareness on osteoarthritis and the growing investments in research and development field by pharma companies which is assisting to the osteoarthritis market growth in this region. The acquisition of modern technologies of medicine and the presence of major market players are expected to drive the growth of the market. The pipeline development of OA market is strong with new developments which is further expected to boost the growth of the market.
Segmentation
Type
PRODUCT OVERVIEW:
The global Osteoarthritis market size was USD 5.85 billion in 2021 and projected to grow from USD 6.9 billion in 2023 to USD 15 billion by 2032, exhibiting a CAGR of 9.0% during the forecast period
Osteoarthritis (OA) is a common condition which affects the shoulders, fingers, knees, feet, back, hips, and neck joints. The progressive deterioration of the joint cartilage is its characteristic. OA can be identified through X-ray, medical assessment, lab tests, arthroscopic, joint fluid analysis, and magnetic resonance imaging (MRI) scans. Several surgical methods & drugs are preferred to treat the indications and symptoms. Few symptoms of OA are stiffness, discomfort, oedema, lack of flexibility, chronic pain, bone spurs, and sleep disruptions. The poor dietary habits, sedentary lifestyle, increased obesity and blood sugar levels are a major reason for acquiring OA.
MARKET HIGHLIGHTS
Osteoarthritis Market is expected to project a CAGR of 9.0% during forecast period, 2022-2032
Osteoarthritis market is expected to reach USD 15 billion at a CAGR of 9.0% during forecast period owing to the increasing awareness about Osteoarthritis and the accessibility to advanced treatments are boosting the growth of osteoarthritis treatment. The increasing demand for minimal invasive non-surgical treatments assist in the growth of the osteoarthritis market.
OSTEOARTHRITIS MARKET SEGMENTATION:
Spinal Osteoarthritis segment is expected to dominate during the forecast period
Osteoarthritis Market is classified based on the Type into Hip Osteoarthritis, Knee Osteoarthritis, Foot & Ankle Osteoarthritis, Shoulder Osteoarthritis, Spinal Osteoarthritis. Spinal Osteoarthritis segment is expected to dominate market during the forecast period owing to the increasing acquirance of sedentary lifestyles, rising obesity rates which is expected to drive the spinal osteoarthritis market growth. The rising preference of minimal invasive procedures of surgery and the advancements of new treatments are aiding in the growth of the market.
Imagining segment is expected to dominate during the forecast period
MARKET DYNAMICS:
Growth Drivers
- Growing Demand for Osteoarthritis Products is Expected to Drive Market Growth
- Expansion of New Therapies is Expected to Boost the Market Growth
- Incidence of Cardiovascular Diseases May Restrain the Market Growth
- Pfizer Inc
- Abbott
- Novartis AG
- Eli Lilly and Company
- Bayer AG
- Johnson & Johnson
- ABIOGEN PHARMA S.p.A
- Merck Sharp & Dohme Corp.
- Apotex Inc.
- TissueGene Inc.
- Ampio Pharmaceuticals Inc.
- Mylan N.V.
- Tolmar Pharmaceuticals, Inc.
- Other Prominent Players
Osteoarthritis Market is segmented based on regional analysis into five major regions: North America, Latin America, Europe, Asia Pacific and the Middle East and Africa. North America region dominated the Osteoarthritis Market in 2021 and is also expected to dominate over the forecast period owing to the increasing awareness on osteoarthritis and the growing investments in research and development field by pharma companies which is assisting to the osteoarthritis market growth in this region. The acquisition of modern technologies of medicine and the presence of major market players are expected to drive the growth of the market. The pipeline development of OA market is strong with new developments which is further expected to boost the growth of the market.
Segmentation
Type
- Hip Osteoarthritis
- Knee Osteoarthritis
- Foot & Ankle Osteoarthritis
- Shoulder Osteoarthritis
- Spinal Osteoarthritis
- Analgesics
- Corticosteroids
- Viscosupplementation agents
- Nonsteroidal anti-inflammatory drugs (NSAIDS)
- Imagining
- Joint Fluid Analysis
- Oral Route
- Topical Route
- Medication
- Therapy
- Surgery
- Hospitals Pharmacy
- E-Commerce
- Retail Pharmacy
- Drug Store
- Prescription Drugs
- Over-The-Counter Drugs
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis
1 EXECUTIVE SUMMARY
1.1. Regional Market Share
1.2. Business Trends
1.3. Osteoarthritis Market: COVID-19 Outbreak
1.4. Regional Trends
1.5. Segmentation Snapshot
2 RESEARCH METHODOLOGY
2.1. Research Objective
2.2. Research Approach
2.3. Data Sourcing and Methodology
2.4. Primary Research
2.5. Secondary Research
2.5.1. Paid Sources
2.5.2. Public Sources
2.6. Market Size Estimation and Data Triangulation
3 MARKET CHARACTERISTICS
3.1. Market Definition
3.2. Osteoarthritis Market: COVID-19 Impact
3.3. Key Segmentations
3.4. Key Developments
3.5. Allied Industry Data
4 OSTEOARTHRITIS MARKET – INDUSTRY INSIGHTS
4.1. Industry Segmentation
4.2. COVID-19 overview on world economy
4.3. Industry ecosystem Channel analysis
4.4. Innovation & Sustainability
5 MACROECONOMIC INDICATORS
6 RECENT DEVELOPMENTS
7 MARKET DYNAMICS
7.1. Introduction
7.2. Growth Drivers
7.3. Market Opportunities
7.4. Market Restraints
7.5. Market Trends
8 RISK ANALYSIS
9 MARKET ANALYSIS
9.1. Porters Five Forces
9.2. PEST Analysis
9.2.1. Political
9.2.2. Economic
9.2.3. Social
9.2.4. Technological
10 OSTEOARTHRITIS MARKET
10.1. Overview
10.2. Historical Analysis (2016-2020)
10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast
11 OSTEOARTHRITIS MARKET SIZE & FORECAST 2022A-2032F
11.1. Overview
11.2. Key Findings
11.3. Market Segmentation
11.3.1. By Type
11.3.1.1. Hip Osteoarthritis
11.3.1.1.1. By Value (USD Million) 2022-2032F
11.3.1.1.2. Market Share (%) 2022-2032F
11.3.1.1.3. Y-o-Y Growth (%) 2022-2032F
11.3.1.2. Knee Osteoarthritis
11.3.1.2.1. By Value (USD Million) 2022-2032F
11.3.1.2.2. Market Share (%) 2022-2032F
11.3.1.2.3. Y-o-Y Growth (%) 2022-2032F
11.3.1.3. Foot & Ankle Osteoarthritis
11.3.1.3.1. By Value (USD Million) 2022-2032F
11.3.1.3.2. Market Share (%) 2022-2032F
11.3.1.3.3. Y-o-Y Growth (%) 2022-2032F
11.3.1.4. Shoulder Osteoarthritis
11.3.1.4.1. By Value (USD Million) 2022-2032F
11.3.1.4.2. Market Share (%) 2022-2032F
11.3.1.4.3. Y-o-Y Growth (%) 2022-2032F
11.3.1.5. Spinal Osteoarthritis
11.3.1.5.1. By Value (USD Million) 2022-2032F
11.3.1.5.2. Market Share (%) 2022-2032F
11.3.1.5.3. Y-o-Y Growth (%) 2022-2032F
11.3.2. By Drug Type
11.3.2.1. Analgesics
11.3.2.1.1. By Value (USD Million) 2022-2032F
11.3.2.1.2. Market Share (%) 2022-2032F
11.3.2.1.3. Y-o-Y Growth (%) 2022-2032F
11.3.2.2. Corticosteroids
11.3.2.2.1. By Value (USD Million) 2022-2032F
11.3.2.2.2. Market Share (%) 2022-2032F
11.3.2.2.3. Y-o-Y Growth (%) 2022-2032F
11.3.2.3. Viscosupplementation agents
11.3.2.3.1. By Value (USD Million) 2022-2032F
11.3.2.3.2. Market Share (%) 2022-2032F
11.3.2.3.3. Y-o-Y Growth (%) 2022-2032F
11.3.2.4. Nonsteroidal anti-inflammatory drugs {NSAIDS}
11.3.2.4.1. By Value (USD Million) 2022-2032F
11.3.2.4.2. Market Share (%) 2022-2032F
11.3.2.4.3. Y-o-Y Growth (%) 2022-2032F
11.3.3. By Diagnosis
11.3.3.1. Imagining
11.3.3.1.1. By Value (USD Million) 2022-2032F
11.3.3.1.2. Market Share (%) 2022-2032F
11.3.3.1.3. Y-o-Y Growth (%) 2022-2032F
11.3.3.2. Joint Fluid Analysis
11.3.3.2.1. By Value (USD Million) 2022-2032F
11.3.3.2.2. Market Share (%) 2022-2032F
11.3.3.2.3. Y-o-Y Growth (%) 2022-2032F
11.3.4. By Route of Administration
11.3.4.1. Parenteral Route
11.3.4.1.1. By Value (USD Million) 2022-2032F
11.3.4.1.2. Market Share (%) 2022-2032F
11.3.4.1.3. Y-o-Y Growth (%) 2022-2032F
11.3.4.2. Oral Route
11.3.4.2.1. By Value (USD Million) 2022-2032F
11.3.4.2.2. Market Share (%) 2022-2032F
11.3.4.2.3. Y-o-Y Growth (%) 2022-2032F
11.3.4.3. Topical Route
11.3.4.3.1. By Value (USD Million) 2022-2032F
11.3.4.3.2. Market Share (%) 2022-2032F
11.3.4.3.3. Y-o-Y Growth (%) 2022-2032F
11.3.5. By Treatment
11.3.5.1. Medication
11.3.5.1.1. By Value (USD Million) 2022-2032F
11.3.5.1.2. Market Share (%) 2022-2032F
11.3.5.1.3. Y-o-Y Growth (%) 2022-2032F
11.3.5.2. Therapy
11.3.5.2.1. By Value (USD Million) 2022-2032F
11.3.5.2.2. Market Share (%) 2022-2032F
11.3.5.2.3. Y-o-Y Growth (%) 2022-2032F
11.3.5.3. Surgery
11.3.5.3.1. By Value (USD Million) 2022-2032F
11.3.5.3.2. Market Share (%) 2022-2032F
11.3.5.3.3. Y-o-Y Growth (%) 2022-2032F
11.3.6. By Distribution Channel
11.3.6.1. Hospitals Pharmacy
11.3.6.1.1. By Value (USD Million) 2022-2032F
11.3.6.1.2. Market Share (%) 2022-2032F
11.3.6.1.3. Y-o-Y Growth (%) 2022-2032F
11.3.6.2. E-Commerce
11.3.6.2.1. By Value (USD Million) 2022-2032F
11.3.6.2.2. Market Share (%) 2022-2032F
11.3.6.2.3. Y-o-Y Growth (%) 2022-2032F
11.3.6.3. Retail Pharmacy
11.3.6.3.1. By Value (USD Million) 2022-2032F
11.3.6.3.2. Market Share (%) 2022-2032F
11.3.6.3.3. Y-o-Y Growth (%) 2022-2032F
11.3.6.4. Drug Store
11.3.6.4.1. By Value (USD Million) 2022-2032F
11.3.6.4.2. Market Share (%) 2022-2032F
11.3.6.4.3. Y-o-Y Growth (%) 2022-2032F
11.3.7. By Purchasing Pattern
11.3.7.1. Prescription Drugs
11.3.7.1.1. By Value (USD Million) 2022-2032F
11.3.7.1.2. Market Share (%) 2022-2032F
11.3.7.1.3. Y-o-Y Growth (%) 2022-2032F
11.3.7.2. Over-The-Counter Drugs
11.3.7.2.1. By Value (USD Million) 2022-2032F
11.3.7.2.2. Market Share (%) 2022-2032F
11.3.7.2.3. Y-o-Y Growth (%) 2022-2032F
12 NORTH AMERICA OSTEOARTHRITIS MARKET SIZE & FORECAST 2022A-2032F
12.1. Overview
12.2. Key Findings
12.3. Market Segmentation
12.3.1. By Type
12.3.2. By Drug Type
12.3.3. By Diagnosis
12.3.4. By Route of Administration
12.3.5. By Treatment
12.3.6. By Distribution Channel
12.3.7. By Purchasing Pattern
12.4. Country
12.4.1. United States
12.4.2. Canada
13 EUROPE OSTEOARTHRITIS MARKET SIZE & FORECAST 2022A-2032F
13.1. Overview
13.2. Key Findings
13.3. Market Segmentation
13.3.1. By Type
13.3.2. By Drug Type
13.3.3. By Diagnosis
13.3.4. By Route of Administration
13.3.5. By Treatment
13.3.6. By Distribution Channel
13.3.7. By Purchasing Pattern
13.4. Country
13.4.1. Germany
13.4.2. United Kingdom
13.4.3. France
13.4.4. Italy
13.4.5. Spain
13.4.6. Russia
13.4.7. Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)
14 ASIA OSTEOARTHRITIS MARKET SIZE & FORECAST 2022A-2032F
14.1. Overview
14.2. Key Findings
14.3. Market Segmentation
14.3.1. By Type
14.3.2. By Drug Type
14.3.3. By Diagnosis
14.3.4. By Route of Administration
14.3.5. By Treatment
14.3.6. By Distribution Channel
14.3.7. By Purchasing Pattern
14.4. By Country
14.4.1. India
14.4.2. China
14.4.3. South Korea
14.4.4. Japan
14.4.5. Rest of APAC
15 MIDDLE EAST AND AFRICA OSTEOARTHRITIS MARKET SIZE & FORECAST 2022A-2032F
15.1. Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1. By Type
15.3.2. By Drug Type
15.3.3. By Diagnosis
15.3.4. By Route of Administration
15.3.5. By Treatment
15.3.6. By Distribution Channel
15.3.7. By Purchasing Pattern
15.4. Country
15.4.1. Israel
15.4.2. GCC
15.4.3. North Africa
15.4.4. South Africa
15.4.5. Rest of Middle East and Africa
16 LATIN AMERICA OSTEOARTHRITIS MARKET SIZE & FORECAST 2022A-2032F
16.1. Overview
16.2. Key Findings
16.3. Market Segmentation
16.3.1. By Type
16.3.2. By Drug Type
16.3.3. By Diagnosis
16.3.4. By Route of Administration
16.3.5. By Treatment
16.3.6. By Distribution Channel
16.3.7. By Purchasing Pattern
16.4. Country
16.4.1. Mexico
16.4.2. Brazil
16.4.3. Rest of Latin America
17 COMPETITIVE LANDSCAPE
17.1. Company market share, 2021
17.2. Key player overview
17.3. Key stakeholders
18 COMPANY PROFILES
18.1. Pfizer Inc
18.1.1. Company Overview
18.1.2. Financial Overview
18.1.3. Key Product; Analysis
18.1.4. Company Assessment
18.1.4.1. Product Portfolio
18.1.4.2. Key Clients
18.1.4.3. Market Share
18.1.4.4. Recent News & Development (Last 3 Yrs.)
18.1.4.5. Executive Team
18.2. Abbott
18.3. Novartis AG
18.4. Eli Lilly and Company
18.5. Bayer AG
18.6. Johnson & Johnson
18.7. ABIOGEN PHARMA S.p.A
18.8. Merck Sharp & Dohme Corp.
18.9. Apotex Inc.
18.10. TissueGene Inc.
18.11. Ampio Pharmaceuticals Inc.
18.12. Mylan N.V.
18.13. Tolmar Pharmaceuticals, Inc.
18.14. Other Prominent Players
19 APPENDIX
20 CONSULTANT RECOMMENDATION
1.1. Regional Market Share
1.2. Business Trends
1.3. Osteoarthritis Market: COVID-19 Outbreak
1.4. Regional Trends
1.5. Segmentation Snapshot
2 RESEARCH METHODOLOGY
2.1. Research Objective
2.2. Research Approach
2.3. Data Sourcing and Methodology
2.4. Primary Research
2.5. Secondary Research
2.5.1. Paid Sources
2.5.2. Public Sources
2.6. Market Size Estimation and Data Triangulation
3 MARKET CHARACTERISTICS
3.1. Market Definition
3.2. Osteoarthritis Market: COVID-19 Impact
3.3. Key Segmentations
3.4. Key Developments
3.5. Allied Industry Data
4 OSTEOARTHRITIS MARKET – INDUSTRY INSIGHTS
4.1. Industry Segmentation
4.2. COVID-19 overview on world economy
4.3. Industry ecosystem Channel analysis
4.4. Innovation & Sustainability
5 MACROECONOMIC INDICATORS
6 RECENT DEVELOPMENTS
7 MARKET DYNAMICS
7.1. Introduction
7.2. Growth Drivers
7.3. Market Opportunities
7.4. Market Restraints
7.5. Market Trends
8 RISK ANALYSIS
9 MARKET ANALYSIS
9.1. Porters Five Forces
9.2. PEST Analysis
9.2.1. Political
9.2.2. Economic
9.2.3. Social
9.2.4. Technological
10 OSTEOARTHRITIS MARKET
10.1. Overview
10.2. Historical Analysis (2016-2020)
10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast
11 OSTEOARTHRITIS MARKET SIZE & FORECAST 2022A-2032F
11.1. Overview
11.2. Key Findings
11.3. Market Segmentation
11.3.1. By Type
11.3.1.1. Hip Osteoarthritis
11.3.1.1.1. By Value (USD Million) 2022-2032F
11.3.1.1.2. Market Share (%) 2022-2032F
11.3.1.1.3. Y-o-Y Growth (%) 2022-2032F
11.3.1.2. Knee Osteoarthritis
11.3.1.2.1. By Value (USD Million) 2022-2032F
11.3.1.2.2. Market Share (%) 2022-2032F
11.3.1.2.3. Y-o-Y Growth (%) 2022-2032F
11.3.1.3. Foot & Ankle Osteoarthritis
11.3.1.3.1. By Value (USD Million) 2022-2032F
11.3.1.3.2. Market Share (%) 2022-2032F
11.3.1.3.3. Y-o-Y Growth (%) 2022-2032F
11.3.1.4. Shoulder Osteoarthritis
11.3.1.4.1. By Value (USD Million) 2022-2032F
11.3.1.4.2. Market Share (%) 2022-2032F
11.3.1.4.3. Y-o-Y Growth (%) 2022-2032F
11.3.1.5. Spinal Osteoarthritis
11.3.1.5.1. By Value (USD Million) 2022-2032F
11.3.1.5.2. Market Share (%) 2022-2032F
11.3.1.5.3. Y-o-Y Growth (%) 2022-2032F
11.3.2. By Drug Type
11.3.2.1. Analgesics
11.3.2.1.1. By Value (USD Million) 2022-2032F
11.3.2.1.2. Market Share (%) 2022-2032F
11.3.2.1.3. Y-o-Y Growth (%) 2022-2032F
11.3.2.2. Corticosteroids
11.3.2.2.1. By Value (USD Million) 2022-2032F
11.3.2.2.2. Market Share (%) 2022-2032F
11.3.2.2.3. Y-o-Y Growth (%) 2022-2032F
11.3.2.3. Viscosupplementation agents
11.3.2.3.1. By Value (USD Million) 2022-2032F
11.3.2.3.2. Market Share (%) 2022-2032F
11.3.2.3.3. Y-o-Y Growth (%) 2022-2032F
11.3.2.4. Nonsteroidal anti-inflammatory drugs {NSAIDS}
11.3.2.4.1. By Value (USD Million) 2022-2032F
11.3.2.4.2. Market Share (%) 2022-2032F
11.3.2.4.3. Y-o-Y Growth (%) 2022-2032F
11.3.3. By Diagnosis
11.3.3.1. Imagining
11.3.3.1.1. By Value (USD Million) 2022-2032F
11.3.3.1.2. Market Share (%) 2022-2032F
11.3.3.1.3. Y-o-Y Growth (%) 2022-2032F
11.3.3.2. Joint Fluid Analysis
11.3.3.2.1. By Value (USD Million) 2022-2032F
11.3.3.2.2. Market Share (%) 2022-2032F
11.3.3.2.3. Y-o-Y Growth (%) 2022-2032F
11.3.4. By Route of Administration
11.3.4.1. Parenteral Route
11.3.4.1.1. By Value (USD Million) 2022-2032F
11.3.4.1.2. Market Share (%) 2022-2032F
11.3.4.1.3. Y-o-Y Growth (%) 2022-2032F
11.3.4.2. Oral Route
11.3.4.2.1. By Value (USD Million) 2022-2032F
11.3.4.2.2. Market Share (%) 2022-2032F
11.3.4.2.3. Y-o-Y Growth (%) 2022-2032F
11.3.4.3. Topical Route
11.3.4.3.1. By Value (USD Million) 2022-2032F
11.3.4.3.2. Market Share (%) 2022-2032F
11.3.4.3.3. Y-o-Y Growth (%) 2022-2032F
11.3.5. By Treatment
11.3.5.1. Medication
11.3.5.1.1. By Value (USD Million) 2022-2032F
11.3.5.1.2. Market Share (%) 2022-2032F
11.3.5.1.3. Y-o-Y Growth (%) 2022-2032F
11.3.5.2. Therapy
11.3.5.2.1. By Value (USD Million) 2022-2032F
11.3.5.2.2. Market Share (%) 2022-2032F
11.3.5.2.3. Y-o-Y Growth (%) 2022-2032F
11.3.5.3. Surgery
11.3.5.3.1. By Value (USD Million) 2022-2032F
11.3.5.3.2. Market Share (%) 2022-2032F
11.3.5.3.3. Y-o-Y Growth (%) 2022-2032F
11.3.6. By Distribution Channel
11.3.6.1. Hospitals Pharmacy
11.3.6.1.1. By Value (USD Million) 2022-2032F
11.3.6.1.2. Market Share (%) 2022-2032F
11.3.6.1.3. Y-o-Y Growth (%) 2022-2032F
11.3.6.2. E-Commerce
11.3.6.2.1. By Value (USD Million) 2022-2032F
11.3.6.2.2. Market Share (%) 2022-2032F
11.3.6.2.3. Y-o-Y Growth (%) 2022-2032F
11.3.6.3. Retail Pharmacy
11.3.6.3.1. By Value (USD Million) 2022-2032F
11.3.6.3.2. Market Share (%) 2022-2032F
11.3.6.3.3. Y-o-Y Growth (%) 2022-2032F
11.3.6.4. Drug Store
11.3.6.4.1. By Value (USD Million) 2022-2032F
11.3.6.4.2. Market Share (%) 2022-2032F
11.3.6.4.3. Y-o-Y Growth (%) 2022-2032F
11.3.7. By Purchasing Pattern
11.3.7.1. Prescription Drugs
11.3.7.1.1. By Value (USD Million) 2022-2032F
11.3.7.1.2. Market Share (%) 2022-2032F
11.3.7.1.3. Y-o-Y Growth (%) 2022-2032F
11.3.7.2. Over-The-Counter Drugs
11.3.7.2.1. By Value (USD Million) 2022-2032F
11.3.7.2.2. Market Share (%) 2022-2032F
11.3.7.2.3. Y-o-Y Growth (%) 2022-2032F
12 NORTH AMERICA OSTEOARTHRITIS MARKET SIZE & FORECAST 2022A-2032F
12.1. Overview
12.2. Key Findings
12.3. Market Segmentation
12.3.1. By Type
12.3.2. By Drug Type
12.3.3. By Diagnosis
12.3.4. By Route of Administration
12.3.5. By Treatment
12.3.6. By Distribution Channel
12.3.7. By Purchasing Pattern
12.4. Country
12.4.1. United States
12.4.2. Canada
13 EUROPE OSTEOARTHRITIS MARKET SIZE & FORECAST 2022A-2032F
13.1. Overview
13.2. Key Findings
13.3. Market Segmentation
13.3.1. By Type
13.3.2. By Drug Type
13.3.3. By Diagnosis
13.3.4. By Route of Administration
13.3.5. By Treatment
13.3.6. By Distribution Channel
13.3.7. By Purchasing Pattern
13.4. Country
13.4.1. Germany
13.4.2. United Kingdom
13.4.3. France
13.4.4. Italy
13.4.5. Spain
13.4.6. Russia
13.4.7. Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)
14 ASIA OSTEOARTHRITIS MARKET SIZE & FORECAST 2022A-2032F
14.1. Overview
14.2. Key Findings
14.3. Market Segmentation
14.3.1. By Type
14.3.2. By Drug Type
14.3.3. By Diagnosis
14.3.4. By Route of Administration
14.3.5. By Treatment
14.3.6. By Distribution Channel
14.3.7. By Purchasing Pattern
14.4. By Country
14.4.1. India
14.4.2. China
14.4.3. South Korea
14.4.4. Japan
14.4.5. Rest of APAC
15 MIDDLE EAST AND AFRICA OSTEOARTHRITIS MARKET SIZE & FORECAST 2022A-2032F
15.1. Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1. By Type
15.3.2. By Drug Type
15.3.3. By Diagnosis
15.3.4. By Route of Administration
15.3.5. By Treatment
15.3.6. By Distribution Channel
15.3.7. By Purchasing Pattern
15.4. Country
15.4.1. Israel
15.4.2. GCC
15.4.3. North Africa
15.4.4. South Africa
15.4.5. Rest of Middle East and Africa
16 LATIN AMERICA OSTEOARTHRITIS MARKET SIZE & FORECAST 2022A-2032F
16.1. Overview
16.2. Key Findings
16.3. Market Segmentation
16.3.1. By Type
16.3.2. By Drug Type
16.3.3. By Diagnosis
16.3.4. By Route of Administration
16.3.5. By Treatment
16.3.6. By Distribution Channel
16.3.7. By Purchasing Pattern
16.4. Country
16.4.1. Mexico
16.4.2. Brazil
16.4.3. Rest of Latin America
17 COMPETITIVE LANDSCAPE
17.1. Company market share, 2021
17.2. Key player overview
17.3. Key stakeholders
18 COMPANY PROFILES
18.1. Pfizer Inc
18.1.1. Company Overview
18.1.2. Financial Overview
18.1.3. Key Product; Analysis
18.1.4. Company Assessment
18.1.4.1. Product Portfolio
18.1.4.2. Key Clients
18.1.4.3. Market Share
18.1.4.4. Recent News & Development (Last 3 Yrs.)
18.1.4.5. Executive Team
18.2. Abbott
18.3. Novartis AG
18.4. Eli Lilly and Company
18.5. Bayer AG
18.6. Johnson & Johnson
18.7. ABIOGEN PHARMA S.p.A
18.8. Merck Sharp & Dohme Corp.
18.9. Apotex Inc.
18.10. TissueGene Inc.
18.11. Ampio Pharmaceuticals Inc.
18.12. Mylan N.V.
18.13. Tolmar Pharmaceuticals, Inc.
18.14. Other Prominent Players
19 APPENDIX
20 CONSULTANT RECOMMENDATION
